Cephalexin for Oral Suspension USP — Class II drug recall D-0380-2019
Terminated recall by Lupin Pharmaceuticals Inc., reported 2019-01-23, distributed nationwide. CGMP Deviation; manufacturing batch record could not be located
| Recall number | D-0380-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2019-01-07 |
| Classified | 2019-01-16 |
| Reported by FDA | 2019-01-23 |
| Terminated | 2020-07-08 |
| Distributed | Nationwide (US) |
| Quantity | 7,215 bottles |
| Reason classes | cgmp |
| NDC | 68180-0124-02 |
| Lot numbers | F602820 |
| Expiration dates | 2019-12-20 |
Product
Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India ---- NDC 68180-0124-02
Reason for recall
CGMP Deviation; manufacturing batch record could not be located
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0380-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.